Views 180
Citations 0
Nov 2012

Plasma Anti–Amyloid-β Autoantibodies in All Alzheimer Disease Types—Reply

Author Affiliations

Author Affiliations: INSERM, UMRS 938 (Drs Dorothée and Aucouturier); UPMC Univ-Paris6 (Drs Dorothée and Aucouturier); CRICM, UPMC Univ Paris 6, Pitie-Salpetriere Hospital (Drs de Souza and Sarazin); Alzheimer Institute, Research and Resource Memory Centre, Centre de Reference de Demences Rares, Centre de reference maladie d’Alzheimer jeune, AP-HP, Pitie-Salpetriere Hospital (Drs de Souza and Sarazin), Paris, France.

Arch Neurol. 2012;69(11):1525-1527. doi:10.1001/archneurol.2012.2779

In reply

The question raised by Tremolizzo and colleagues relates to their recent observation that treatments with acetylcholinesterase inhibitors could impact the circulating levels of anti–amyloid β (Aβ) antibodies.1 As a matter of fact, our observation of significant differences in anti-Aβ antibody levels between patients with typical Alzheimer disease (AD) and patients with posterior cortical atrophy with evidence of AD (PCA-AD)2 could have been influenced by external factors including treatments. However, this possibility may be ruled out for the following 2 main reasons.

First Page Preview View Large
First page PDF preview
First page PDF preview